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Abstract
Background: Control of soil-transmitted helminth (STH) infections relies on the periodic and long-term administration of
anthelmintic drugs to high-risk groups, particularly school-age children living in endemic areas. There is limited data on the
effectiveness of long-term periodic anthelmintic treatment on the prevalence of STHs, particularly from operational
programmes. The current study investigated the impact of 15 to 17 years of treatment with the broad-spectrum
anthelmintic ivermectin, used for the control of onchocerciasis, on STH prevalence and intensity in school-age and pre-
school children.
Methods and Findings: A cross-sectional study was conducted in communities that had received annual or twice-annual
ivermectin treatments and geographically adjacent communities that had not received treatment in two districts of
Esmeraldas Province in Ecuador. Stool samples were collected from school-age children and examined for STH infection
using the Kato-Katz and formol-ether concentration methods. Samples were collected also from pre-school children and
examined by the formol-ether concentration method. Data on risk factors for STH infection were collected by parental
questionnaire. We sampled a total of 3,705 school-age children (6–16 years) from 31 treated and 27 non-treated
communities, and 1,701 pre-school children aged 0–5 years from 18 treated and 18 non-treated communities. Among
school-age children, ivermectin treatment had significant effects on the prevalence (adjusted OR= 0.06, 95% CI 0.03–0.14)
and intensity of Trichuris trichiura infection (adjusted RR=0.28, 95% CI 0.11–0.70), but appeared to have no impact on
Ascaris lumbricoides or hookworm infection. Reduced prevalence and intensities of T. trichiura infection were observed
among children not eligible to receive ivermectina, providing some evidence of reduced transmission of T. trichiura
infection in communities receiving mass ivermectin treatments.
Conclusion: Annual and twice-annual treatments with ivermectin over a period of up to 17 years may have had a significant
impact on T. trichiura infection. The present data indicate that the long-term control of onchocerciasis with ivermectin may
provide additional health benefits by reducing infections with trichuriasis. The addition of a second anthelmintic drug such
as albendazole may be useful for a long-term effect on A. lumbricoides infection.
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Introduction
Soil-transmitted helminths (STHs, also known as geohelminths
or intestinal helminths) are important infectious diseases of
humans and are estimated to infect over 2 billion humans
worldwide [1], being particularly prevalent in poor populations
living in tropical and sub-tropical regions of developing countries
[2]. Soil-transmitted helminths include Ascaris lumbricoides, Trichuris
trichiura, hookworm, and Strongyloides stercoralis, and are considered
to be a major cause of morbidity related to impaired nutrition and
poor childhood growth [3,4].
STH control strategies are focused currently on mass treatment
with broad spectrum anthelminthic drugs with the aim of reducing
morbidity through reductions in parasite burdens that are strongly
associated with risk of morbidity [5,6]. Because of a high risk of re-
infection in endemic areas, treatments have to be administered
repeatedly for long periods of time. WHO has recommended the
use of one of albendazole, mebendazole, levamisole and pyrantel
www.plosntds.org 1 September 2008 | Volume 2 | Issue 9 | e293for STH control [7]. The 4 drugs have variable efficacy against
different STH parasites.
Ivermectin is a broad-spectrum anthelmintic drug used for the
control of filarial infections including onchocerciasis and lymphatic
filariasis [8,9]. Ivermectin has also efficacy against STH infections
- it is highly effective against ascariasis and strongyloidiasis
[10,11,12,13,14] for which it has superior or comparable efficacy
to albendazole [10,12], is of moderate efficacy against trichuriasis
for which it has comparable efficacy to albendazole [10,11,13,14]
but is less effective than albendazole against hookworm [12,13,14].
The distribution of ivermectin forms the basis of onchocerciasis
control programmes worldwide. In Ecuador, the National
Programme for the Elimination of Onchocerciasis has adminis-
tered annual or twice-annual mass treatments with ivermectin over
the past 17 year as the primary control strategy in endemic
communities and has achieved high rates of coverage. We have
reported previously that ivermectin control has been extremely
effective for the control of onchocerciasis and may have eliminated
the infection from some infection foci in Ecuador [15].
To investigate the long-term effect of ivermectin treatment used
for the control of onchocerciasis on the prevalence of infection and
transmission with STH parasites, we compared the prevalence and
intensities of STH infections among children living in communities
that had received long-term ivermectin treatments with those that
had not received ivermectin in Esmeraldas Province in Ecuador.
Previous surveys conducted in this area have shown high rates of
STH infection [16,17].
Methods
Study area and population
This study was conducted in rural Afro-Ecuadorian communi-
ties located in the principal onchocerciasis focus or in adjacent
communities in the districts of Eloy Alfaro and San Lorenzo in
Esmeraldas province, in northeastern Ecuador. The area is
equatorial rain forest at an altitude of below 100 m above sea
level and the characteristics of the study area and population are
described in detail elsewhere [18].
Study design
A cross-sectional study was conducted to compare the prevalence
and intensity of STH infections between children from treated and
non-treated Afro-Ecuadoriancommunities. Selection of ivermectin-
treated study communities was based on the 6-monthly treatment
schedule with ivermectin of the Ecuadorian Elimination Pro-
gramme for Onchocerciasis. Non-treated communities with a
recent census were selected to be as similar as possible to treated
communities with respect to geographic location (non-treated
communities were geographically close to treated communities
within the 2 study Districts), size (communities with schools having
.250 pupils were excluded), and similar economic activities (e.g.
subsistence agriculture, logging, and hunting). None of the non-
treated communities had received previous mass treatments with
ivermectin. STH infections were examined in two distinct age
groups using the community census: 1) school-age (6–16 years)
including children attending and not attending community schools;
and 2) pre-school (0–5 years). These age groups separated
approximately children eligible to receive ivermectin (.15 kg) from
those not eligible, allowing an assessment of the effect of ivermectin
treatments on the transmission of STH infections. Assessment of
pre-school children was performed for a sample in the treated and
non-treated communities.
Data collection
The field study was conducted between March 2005 and May
2007. Stool collections were performed immediately before 6-
monthly ivermectin distributions in treated communities. Annu-
ally-updated censuses were used to identify eligible children. A
register of the number of treatments received by each child was
obtained from the National Programme for the Elimination of
Onchocerciasis. A questionnaire was administered to the parent or
guardian of each child by trained field workers to obtain
information about risk factors for STH infections including age,
sex, mother’s education level, material goods in the household,
household income, household crowding, access to water, sanita-
tion and recent anthelmintic treatments [18].
Examination of stool samples
Single stool samples were collected from each child and
examined for STH eggs and larvae using the modified Kato-Katz
technique (quantification of Ascaris lumbricoides and Trichuris trichiura
infection) [school-age children only] and formol-ethyl acetate
concentration (detection of all STH infections including hook-
worm and Strongyloides stercoralis) [19] [all children].
Distribution of ivermectin
The National Program for Elimination of Onchocerciasis has
used community-based mass distribution of ivermectin as the main
strategy for the control of Onchocerca volvulus infection since 1990.
There are a total of 119 endemic communities with an estimated
19,420 inhabitants in 2 Provinces in Ecuador and ivermectin
treatment was gradually introduced into all communities over the
period 1990–1997. The number of treatments and the start of
mass distribution vary according to each focus. Mass treatment
was initiated in all communities included in this study between
1990 and 1992, and the period of mass ivermectin treatments for
study communities ranged 15–17 years. Initially, ivermectin was
distributed annually to endemic communities but treatments were
increased to 6-monthly in all communities from 2001. Treatment
Author Summary
Soil-transmitted helminth (intestinal worm) infections are
very common in developing countries and are an
important cause of illness. Mass de-worming treatments
of school children are an important strategy to reduce
illness caused by these infections in communities without
access to clean water and sanitation. Few studies have
examined the effect of repeated mass treatments in the
long-term in controlling these infections. The objective of
the present study was to assess the impact of the drug
ivermectin used for the control of onchocerciasis (river
blindness), that has important effects against intestinal
worms, on the epidemiology of intestinal worms in
children when administered repeatedly for 15–17 years.
We compared the epidemiology of infections between
children living in communities that received ivermectin
with communities that never received the drug. The data
suggest that ivermectin has important differential effects
on intestinal worms with a greater impact on infections
with Trichuris trichiura and little impact on Ascaris
lumbricoides and hookworms infections. Our data suggest
that long-term ivermectin treatments may provide health
benefits through effects on T. trichiura infections but that
the addition of second de-worming drug such as
albendazole may be required for the control of other
intestinal worm infections.
Impact of Ivermectin on STH Infections
www.plosntds.org 2 September 2008 | Volume 2 | Issue 9 | e293coverage with ivermectin has been high and over the period 1990
to 2003, the annual average treatment coverage per treatment
round with ivermectin was 85.2% (range 54.9%–97.9%). The
mean treatment coverage for the two years, 2005–2006, was 98%.
Eligibility criteria for treatment are: weight greater than 15 kg and
free of serious illness (e.g. active tuberculosis, terminal cancer etc),
and for women, not pregnant and not nursing infants up to 3
month of age. Ivermectin is distributed by primary health workers
in each community at a dose of 150 mg/mg and treatments are
directly observed. The population census is used as the basis for
drug distribution [15].
Statistical analysis
STH prevalence was expressed as the percentage of subjects
found positive for each parasite. Comparisons between propor-
tions were performed using an adjusted chi-squared test for
clustered data. ORs for prevalence data were calculated using
multilevel logistic regression models (command, xtlogit) to obtain
robust standard errors that take into account correlated data.
Potential confounding factors were controlled for in the analysis. A
multilevel analysis was used because of the large variation in STH
prevalence between study communities. The intraclass correlation
coefficients for Ascaris and Trichuris infection in this study were 0.29
(95% CI: 0.21–0.39) and 0.13 (95% CI: 0.09–0.18), respectively.
STH intensity was calculated as eggs per gram of stool. Because
stool egg counts were over-dispersed (A. lumbricoides, mean 6,297
epg, variance 5.1610
8; T. trichiura, mean 9746 epg, variance
1.3610
7), a zero-inflated negative binomial (ZINB) model was
used to fit the data. The Vuong test (1.90 (p=0.03) and 11.55
(p,0.001) for A. lumbricoides and T. trichiura, respectively) indicated
that a zero inflated model fit the data better than a standard
negative binomial model [20]. A robust variance estimator was
used to account for clustering by community, and rate ratios (RRs)
and their 95% confidence intervals were estimated. The ZINB
model was fitted manually, and potential confounding factors were
controlled for in multivariate analyses. RRs for infection intensity
indicate the relative increase or decrease in infection intensities in
the treated compared to non-treated groups. A single 0.5 unit fall
in RR represents a 50% greater infection intensity in the untreated
compared to treated group. All analyses were done with STATA
(version 9.0).
Ethics
The study protocol was approved by ethical committee of the
Hospital Pedro Vicente Maldonado, Pichincha Province, Ecuador.
Informed written consent was obtained by a parent or guardian for
all children. All children were offered treatment with a single dose
of 400 mg of albendazole at the end of the study.
Results
Study population and anthelmintic treatment
A total of 3,960 school-age children from 58 communities were
assessed and 3,705 provided a stool sample and were included in
the analysis. School-age children were analysed from 31 (1,752
children) ivermectin-treated and 27 (1,953 children) neighbouring
non-treated communities. The mean cluster size was 54.7 (range:
13–203) children in treated and 69.2 (range: 15–190) in non-
treated communities. Demographic, socioeconomic, and environ-
mental characteristics of the children from treated and non-treated
communities are shown in Table 1. There were differences in
some socioeconomic and environmental characteristics between
the two study groups: treated children tended to have a lower
household income and fewer material goods and a greater
proportion used river water than non-treated children.
The number of doses of ivermectin received by the 1,752
children in the treated communities were: 1–5 doses (12.5%), 6–10
doses (41.3%); 11–15 doses (41.0%) and 16–20 doses (5.2%).
Treatment coverage with ivermectin was high and 79.3% (1,390)
of children had received .75% of designated treatments over the
previous five years. Reported treatments with other anthelmintic
drugs were equally widespread in both treatment (77.5%) and
non-treatment (78.0%) communities over the previous 6 months.
Most treatments were bought directly by parents, were distributed
through schools, or through physician consultations. During the
course of this study there were no programmes of systematic
periodic treatments with other anthelmintic drugs such as
albendazole in any of the study communities. School-based
treatments with albendazole have been given sporadically by
non-governmental organisations, and politically-affiliated groups
(e.g. at the time of local and presidential elections every 4 years).
Community treatments may have important effects on the
transmission of STHs. To investigate this, we analysed stool
samples from children aged 0–5 years that had not received
ivermectin. A total of 776 and 925 children from 18 treated and 18
non-treated communities, respectively, were analysed. Of the 776
children aged 0–5 years from treated communities, 484 (62.8%)
had not received any dose of ivermectin (for reasons of weight
,15 kg), 139 (18.0%) had received 1–2 doses, 96 (12.5%) 3–4
doses, 42 (5.4%) 5–6 doses and 10 (1.3%) 7–8 doses.
Effect of ivermectin treatment on STH infections
Ivermectin treatment was associated with a significant reduction
in the prevalence of infection with any STH parasite (62.8%
treated vs. 86.3% untreated children; adj. OR 0.27, 95% CI 0.15–
0.47, P,0.001) The age-prevalence and age-infection intensity
profiles for A. lumbricoides and T. trichiura infections in treated and
non-treated children are shown in Figure 1. There were trends of
age-associated declines in the prevalence and intensity of both
infections. The prevalence (treated 48.9% vs. non-treated 57.3%,
adjusted OR 0.96, 95% CI 0.45–2.05, P=0.92) and intensity (GM
infection intensity, treated 30.2 vs. untreated 33.7 epg; adjusted
RR 1.51, 95% CI 0.81–2.82, P=0.19) of A. lumbricoides infection
was not different between children from ivermectin-treated and
non-treated communities across the age groupings (Figure 1A and
B) (Table 2 and 3). Both the prevalence (treated 31.1% vs. non-
treated 81.5%, adjusted OR 0.06, 95% CI 0.03–0.14, P,0.001)
and intensity (GM infection intensity, treated 3.9 vs. untreated
132.0 epg; adjusted RR 0.28, 95% CI 0.11–0.70, P=0.007) of T.
trichiura infection were greater in non-treated compared to treated
school children at all age groups (Figure 1C and D) (Table 2 and
3). Ivermectin treatment did not appear to reduce the prevalence
of hookworm infection and, in fact, the prevalence was
significantly greater in treated compared to non-treated children
(treated 14.8% vs. non-treated 3.9%, adjusted OR 5.53, 95% CI
1.81–16.86, P=0.003) (Table 2).
Among pre-school children living in the same communities and
not eligible to receive ivermectin (in treated communities), there
were significantly fewer infections with any STH (untreated 64.8%
vs. treated 40.7%; adjusted for age, sex, and treatment, OR, 0.34,
95% CI 0.21–0.56, P,0.001) and T. trichiura infection (untreated
55.4% vs. treated 15.7%; adj. OR= 0.12, 95% CI 0.07–0.21,
P,0.001)) but not A. lumbricoides infection (untreated 38.4% vs.
treated 33.1%; adjusted OR=0.67, 95% CI 0.38–1.19, P=0.17)
among treated compared to non-treated children. Pre-school
children from the treated communities also had significantly lower
infection intensities with T.trichiura (adj. RR=0.32, 95% CI 0.19–
Impact of Ivermectin on STH Infections
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0.76–3.00, P=0.24) compared to those from non-treated commu-
nities (Table 4 and 5). Because 32.9% of children in the treated
group had received at least one dose of ivermectin, the analysis was
repeated excluding all treated children (925 untreated vs. 471
treated children). The results of these analyses were similar to those
obtained for all pre-school children (e.g. age and sex-adjusted OR
for T. trichiura prevalence, OR 0.11, 95% CI 0.06–0.22, P,0.001).
At the community level there was a lot of variation in the
prevalence of A. lumbricoides between treated and non-treated
communities and no evidence of systematic differences in
prevalence, but for T. trichiura infection, there was a strong trend
Table 1. Characteristics of 3,705 school-age children by ivermectin treatment group.




6–7 300 (15.4) 263 (15.0) 563 (15.2)
8–9 473 (24.2) 415 (23.7) 888 (23.9)
10–11 448 (22.9) 404 (23.0) 852 (23.0)
12–13 453 (23.2) 376 (21.5) 829 (22.4)
14–16 279 (14.3) 294 (16.8) 573 (15.5) 0.655
Sex, %
Girl 983 (50.3) 827 (47.2) 1810 (48.9)
Boy 970 (49.7) 925 (52.8) 1895 (51.1) 0.075
Socioeconomic characteristics
Maternal educational level, %
Secondary completed 156 (8.3) 132 (7.6) 288 (8.0)
Primary completed 753 (40.1) 483 (28.0) 1236 (34.3)
Illiterate or incomplete primary 970 (51.6) 1111 (64.4) 2081 (57.7) 0.087
Household income, %
.150 per month 499 (25.7) 175 (10.2) 674 (18.5)
#150 per month 1441 (74.3) 1537 (89.8) 2978 (81.5) ,0.001
Electric appliances in house,%
3–4 668 (34.2) 350 (20.0) 1018 (27.4)
1–2 1066 (54.6) 963 (55.0) 2029 (54.8)
None 219 (11.2) 439 (25.0) 658 (17.8) ,0.001
Environmental characteristics
Crowding (people per sleeping room), %
#2 512 (26.2) 568 (32.4) 1080 (29.2)
.2 1439 (73.8) 1183 (67.6) 2622 (70.8) 0.130
Bathroom, %
Toilet or latrine 1081 (55.3) 1214 (69.4) 2295 (62.0)
Open ground 872 (44.7) 536 (30.6) 1408 (38.0) 0.118
Drinking water,%
Well 305 (15.6) 30 (1.7) 335 (9.0)
Piped 594 (30.4) 15 (0.9) 609 (16.4)
River or stream 1054 (54.0) 1707 (97.4) 2761 (74.6) ,0.001
Treatment
Recent anthelmintic treatment, %**
Yes 1504 (78.0) 1249 (77.5) 2753 (77.8)
No 279 (14.5) 208 (12.9) 487 (13.8)
Don’t know 145 (7.5) 155 (9.6) 300 (8.4) 0.719
Brackets show percentages.
*There are missing values for maternal education level (100), household income (37), crowding (3) and bathroom (2).
**Anthelmintic treatment within the previous 6 months.
doi:10.1371/journal.pntd.0000293.t001
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communities (data not shown).
Discussion
The control of soil-transmitted helminth (STH) infections is an
important public health strategy targeted at school-age children in
many developing countries, and has been prioritised because of
the important morbid effects attributed to these infections.
Further, such programmes are relatively easy to administer
(through schools) and are considered to be highly cost-effective
[21,22]. Because STH infections are caused by faecal contamina-
tion of the environment, re-infections may be frequent after a
single dose of anthelmintic treatment in highly endemic areas [23],
and because treatment programmes rarely address underlying
causes (e.g. poor sanitation), treatments may have to be
administered periodically for periods of years. There are few
reports of the long-term effects of anthelmintic treatment
programmes on the epidemiology of STH infections; many
studies, both randomized controlled trials [24] and uncontrolled
studies [25], have reported the effect of single doses of anthelmintic
drugs either alone or in combination with follow-up of up to 1 year
post treatment [10]. Few studies have investigated the impact of
periodic treatments with anthelmintic drugs on STH infections for
longer periods–in such studies, follow-up has ranged 2 [26] and 4
years [27].
In the present study, we measured the impact of up to 17 years of
periodic treatments with the broad-spectrum anthelmintic drug,
ivermectin, on both the epidemiology of STH infections in school-age
children and alsothe impact of such treatments on the transmission of
STH infections in pre-school children. Our results provide evidence
that long-term ivermectin treatments may have differential effects on
STH infections, with major effects on T.trichiura, but littleor no effect
on A. lumbricoides and hookworm infections.
The present study had several important strengths. Ivermectin is
a broad-spectrum anthelmintic drug that is effective against STH
infections and has comparable efficacy (except for hookworm) to
albendazole, the most widely used drug in STH control
programmes [10,11,12]. Periodic treatment in this study was
given for periods of between 15 and 17 years, making it, to our
knowledge, the longest documented period of periodic treatments
used for the evaluation of the impact of anthelmintic treatment on
STH infections. Further, the data is from an operational control
programme that was able to achieve high rates of treatment
coverage, and the data obtained reflect, therefore, what an optimal
control programme may be capable of achieving using a strategy
of twice-annual treatments. Other strengths were the availability of
data on the number of ivermectin treatments at the individual
level, censuses that allowed us to identify all children of school age
in each community, the collection of data on important
confounding factors, and the study of a large sample both at the
individual and community levels.
Figure 1. Age-prevalence and age-intensity for Ascaris lumbricoides (graphs A and B, respectively) and Trichuris trichiura (C and D,
respectively) for school-age children treated (open circles) or not treated (closed circles) with ivermectin. Shown are mean values and
95% confidence intervals.
doi:10.1371/journal.pntd.0000293.g001
Impact of Ivermectin on STH Infections
www.plosntds.org 5 September 2008 | Volume 2 | Issue 9 | e293However, the study was cross-sectional rather than prospective
and we did not have data on STH infections before the start of the
intervention. We tried to select comparable non-treated commu-
nities, but there was evidence of differences in some variables
between the treated and non-treated communities at baseline
(Table 1). Although an analytic strategy allowing for these factors
to be controlled in the analysis was used, residual confounding or
systematic bias cannot be excluded. Systematic differences
between communities may explain the higher prevalence of
hookworm observed in treated communities. This observation is
unlikely to be explained by the limited of efficacy of ivermectin
against hookworm infections [12,13,28,29]. The determinants of
the geographic distribution of hookworm and other STH
infections are poorly understood but include factors such as
climate, socioeconomic factors and human behaviour [30]. We do
not have data on climatic variables for these communities, and
there were differences between treated communities with respect
to some socioeconomic indicators (e.g. median income and
material goods in the household) that may explain partly the
geographic distribution of hookworm infection.
The study provided evidence that long-term periodic treatments
with ivermectin may have important effects on the prevalence and
intensity of T. trichiura infections. Previous studies have demon-
strated variable efficacy of ivermectin against T. trichiura infections
after one (35%–88% cure rate) [10,11,13,14] or two doses (100%
cure rate) [13] although studies from Africa showed very limited
efficacy after 1–4 doses of ivermectin (0–11% cure rates)
[12,29,31,32,33]. The present study in which communities had
received ivermectin for 15–17 years provided some evidence for
strong and significant long-term effects against T. trichiura
infections among children receiving treatment (reduction in
prevalence and intensity of 50.4% and 72%, respectively). Further,
Table 2. Impact of ivermectin treatment on STH infections in 3,705 school-age children.
No-Treatment Ivermectin Total Univariate analysis Multivariate analysis
1953 1752 3705 Odds ratio p Odds ratio
* p
(95% CI) (95% CI)
STH infections
Any helminth
Negative 267 (13.7) 652 (37.2) 919 (24.8) 1.0 1.0
Positive 1686 (86.3) 1100 (62.8) 2786 (75.2) 0.24 (0.12–0.45) ,0.001 0.27 (0.15–0.47) ,0.001
A. lumbricoides
Negative 834 (42.7) 895 (51.1) 1729 (46.7) 1.0 1.0
Positive 1119 (57.3) 857 (48.9) 1976 (53.3) 0.81 (0.42–1.53) 0.512 0.96 (0.45–2.05) 0.916
T. trichiura
Negative 362 (18.5) 1208 (68.9) 1570 (42.4) 1.0 1.0
Positive 1591 (81.5) 544 (31.1) 2135 (57.6) 0.09 (0.04–0.18) ,0.001 0.06 (0.03–0.14) ,0.001
Hookworm
Negative 1877 (96.1) 1492 (85.1) 3369 (90.9) 1.0 1.0
Positive 76 (3.9) 260 (14.8) 336 (9.1) 5.71 (2.26–14.43) ,0.001 5.53 (1.81–16.86) 0.003
S. stercoralis
Negative 1939 (99.3) 1750 (99.9) 3689 (99.6) … …
Positive 14 (0.7) 2 (0.1) 16 (0.4) ** **
*ORs adjusted for age, sex, maternal educational level, monthly income, household electric appliances, crowding, bathroom, water source and number of ivermectin
treatments received.
**Cannot be reliably estimated because of small numbers.
doi:10.1371/journal.pntd.0000293.t002
Table 3. Impact of ivermectin treatment on geometric mean infection intensities (GMI) with A.lumbricoides and T.trichiura in 3,705
school-age children.
No-Treatment Ivermectin Univariate analysis Multivariate analysis
1953 (52.7%) 1752 (47.3%) RR p RR
* p
(95% CI) (95% CI)
STH infections
A. lumbricoides, GMI 33.71 30.24 1.88 (1.04–3.37) 0.036 1.51 (0.81–2.82) 0.190
T. trichiura, GMI 132.09 3.91 0.28 (0.18–0.43) ,0.001 0.28 (0.11–0.70) 0.007
GMI, geometric mean intensity.
Rate ratios (RR) were calculated using zero-inflated binomial regression models and adjusted for age, sex and ivermectin treatments.
doi:10.1371/journal.pntd.0000293.t003
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intensity (39.7% and 68%, respectively) among children not
eligible to receive treatment suggest that long-term ivermectin
treatments may suppress the transmission of this infection.
Surprisingly, we did not observe an effect of long-term
ivermectin administration on A. lumbricoides infections. Ivermectin
is extremely effective against this parasite and single dose cure
rates between different studies are consistently greater than 78%
[10,11,12,13,14]. Studies that have examined the effects of
ivermectin against ascariasis have shown that a single dose could
reduce the prevalence and intensity of A. lumbricoides infection for
up to three months after a single treatment [29,34], although
reinfections are an important problem and may occur by 3 months
after treatment [29,31,35]. Previous studies that have examined
the effects of multiple doses of ivermectin against A. lumbricoides
infection for periods of 1–2 years have shown no important effect
of treatments on the prevalence of A. lumbricoides infection [31,33].
Further, in this study we did not observe an impact of ivermectin
treatment on the prevalence or intensity of infection of A.
lumbricoides among children not eligible to receive treatment,
indicating little effect on the transmission of infection.
There are three possible explanations for the possible lack of
long-term effect of ivermectin on ascariasis. Firstly, fertilized A.
lumbricoides adult females are extremely fecund and each may
produce in excess of 200,000 embryonated eggs per day [36],
considerably more than T. trichiura or hookworm females. Ascaris
eggs are extremely resistant to adverse environmental conditions
and may remain infectious for years. Thus, in the absence of
adequate removal of human faeces, exposure to embryonated eggs
in the environment in endemic communities may be difficult to
avoid and reinfection inevitable. A city-wide intervention to
provide sanitation in the city of Salvador in Brazil had dramatic
Table 4. Impact of ivermectin treatment on STH infections in 1,701 pre-school children.
No-Treatment Ivermectin Univariate analysis Multivariate analysis
n=925 n=776 Odds ratio p Odds ratio
* p
(95% CI) (95% CI)
STH infections
Any helminth,
Negative 326 (35.2) 460 (59.3) 1.0 1.0
Positive 599 (64.8) 316 (40.7) 0.33 (0.22–0.50) ,0.001 0.34 (0.21–0.56) ,0.001
A. lumbricoides
Negative 570 (61.6) 519 (66.9) 1.0 1.0
Positive 355 (38.4) 257 (33.1) 0.64 (0.38–1.09) 0.102 0.67 (0.38–1.19) 0.174
T. trichiura
Negative 413 (44.6) 654 (84.3) 1.0 1.0
Positive 512 (55.4) 122 (15.7) 0.12 (0.08–0.20) ,0.001 0.12 (0.07–0.21) ,0.001
Hookworm
Negative 920 (99.5) 768 (99.0) – … … …
Positive 5 (0.5) 8 (1.0) ** **
S. stercoralis
Negative 904 (97.7) 775 (99.9) … … …. …
Positive 21 (2.3) 1 (0.1) ** **
*Odds ratio adjusted by age, sex and ivermectin treatment.
**Cannot be reliably estimated because of small numbers.
doi:10.1371/journal.pntd.0000293.t004
Table 5. Impact of ivermectin treatment on geometric mean infection intensities (GMI) with A. lumbricoides and T. trichiura in
1,701 pre-school children.
No-Treatment Ivermectin Univariate analysis Multivariate analysis
n=925 n=776 RR p RR
* p
(95% CI) (95% CI)
STH infections
A. lumbricoides, GMI 8.57 6.38 1.30 (0.67–2.51) 0.438 1.51 (0.76–3.00) 0.241
T. trichiura, GMI 11.19 0.82 0.26 (0.17–0.39) ,0.001 0.32 (0.19–0.54) ,0.001
Hookworm, GMI 0.02 0.03 ** **
*Rate Ratios (RRs) calculated by zero-inflated negative binomial regression models and adjusted by age, sex and ivermectin treatment.
**Cannot be reliably estimated because of small numbers.
doi:10.1371/journal.pntd.0000293.t005
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STH infections including ascariasis [38] that have been sustained
over many years. A second but perhaps less likely explanation is
the development of drug resistance by A. lumbricoides to ivermectin.
Mass treatments with ivermectin have been administered in these
communities for 15–17 years and the development of drug
resistance by A. lumbricoides could explain the lack of impact of
ivermectin on this infection. Decreased sensitivity of hookworm
infections to mebendazole [39] and pyrantel [40] has been
reported previously, and resistance to ivermectin by gastrointes-
tinal nematodes of animals is widespread [41]. Finally, we do not
have pre-treatment data on the prevalence of ascariasis in treated
communities and it is possible that the prevalence of ascariasis was
higher in treated compared to non-treated communities before the
start of mass treatment with ivermectin between 1990 and 1992.
Data obtained from the pre-treatment period for a group of 158
adults and children from a treated Afro-Ecuadorian community,
not included in the present study, indicated a prevalence of A.
lumbricoides and T. trichiura infections of 58.2% and 59.5%,
respectively [17]. Although such data should be interpreted
cautiously–because of differences in age, study population, and
the diagnostic method used - they may suggest that the prevalence
of ascariasis has not altered greatly since the start of mass
treatment and that long-term ivermectin treatments have had a
relatively greater effect in reducing the prevalence of trichuriasis
than ascariasis.
Conclusions
We have evaluated the impact of long-term treatment with a
broad-spectrum anthelmintic drug, ivermectin, used for the
control of onchocerciasis, on the epidemiology of STH infections
in rural Ecuador. The data indicate that 15–17 years of annual or
twice-annual ivermectin treatments was highly effective against
T.trichiura infections but may have had little impact on infections
with A. lumbricoides and hookworm. Our study provides evidence
that control programmes using ivermectin may provide additional
health benefits by reducing the prevalence and intensity of
infections with trichuriasis. To have a greater impact on ascariasis
and hookworm infections, such programmes could consider the
addition of twice annual albendazole treatments that can be safely
administered with ivermectin [25], although effective reductions in
the prevalence of these infections may require more frequent
periodic treatments. The combination of ivermectin and albenda-
zole has the advantage also of greater efficacy against trichuriasis
than either drug alone [10,11,42]. However, long-term sustainable
control may require interventions that target the underlying causes
of these infections–namely the unsafe disposal and use of human
faeces.
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